Capitolis Liquid Global Markets LLC Purchases Shares of 185,000 Encompass Health Corporation $EHC

Capitolis Liquid Global Markets LLC bought a new position in shares of Encompass Health Corporation (NYSE:EHC) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 185,000 shares of the company’s stock, valued at approximately $19,636,000.

Several other hedge funds have also recently modified their holdings of EHC. Northwestern Mutual Wealth Management Co. lifted its position in shares of Encompass Health by 3,059,159.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock worth $402,640,000 after buying an additional 3,793,358 shares in the last quarter. Norges Bank bought a new position in shares of Encompass Health during the 4th quarter worth approximately $133,221,000. Price T Rowe Associates Inc. MD lifted its position in shares of Encompass Health by 24.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,805,413 shares of the company’s stock worth $510,047,000 after buying an additional 948,202 shares in the last quarter. Millennium Management LLC lifted its position in shares of Encompass Health by 140.0% during the 3rd quarter. Millennium Management LLC now owns 1,223,665 shares of the company’s stock worth $155,430,000 after buying an additional 713,738 shares in the last quarter. Finally, 8 Knots Management LLC bought a new position in shares of Encompass Health during the 2nd quarter worth approximately $78,644,000. Institutional investors own 97.25% of the company’s stock.

Encompass Health Price Performance

Encompass Health stock opened at $98.04 on Thursday. Encompass Health Corporation has a 12 month low of $92.77 and a 12 month high of $127.99. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.76. The business’s 50 day simple moving average is $104.26 and its 200 day simple moving average is $104.23. The company has a market cap of $9.73 billion, a price-to-earnings ratio of 16.37, a PEG ratio of 2.18 and a beta of 0.72.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Thursday, April 30th. The company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.51 by $0.09. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the business earned $1.37 earnings per share. Encompass Health’s revenue for the quarter was up 9.0% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Sell-side analysts forecast that Encompass Health Corporation will post 5.97 EPS for the current year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Wednesday, July 1st will be issued a dividend of $0.19 per share. The ex-dividend date of this dividend is Wednesday, July 1st. This represents a $0.76 dividend on an annualized basis and a yield of 0.8%. Encompass Health’s payout ratio is presently 12.69%.

Insider Transactions at Encompass Health

In other Encompass Health news, EVP Patrick William Tuer sold 682 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $104.56, for a total transaction of $71,309.92. Following the sale, the executive vice president owned 24,755 shares of the company’s stock, valued at $2,588,382.80. The trade was a 2.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on EHC shares. Leerink Partners set a $152.00 target price on shares of Encompass Health in a research report on Friday, May 22nd. Barclays dropped their target price on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 5th. Weiss Ratings reissued a “buy (b-)” rating on shares of Encompass Health in a research report on Monday, June 8th. Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, TD Cowen started coverage on Encompass Health in a research note on Thursday, May 28th. They issued a “buy” rating and a $125.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Encompass Health has an average rating of “Buy” and a consensus price target of $143.86.

Encompass Health Profile

Encompass Health Corporation is a leading provider of post?acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end?of?life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.